When could generic acalabrutinib become available?
The earliest potential availability of generic acalabrutinib hinges on patent expirations. According to DrugPatentWatch.com, the key patents protecting acalabrutinib are expected to expire in 2035 and 2036 [1]. However, patent challenges and other legal maneuvers could alter these timelines.
What are the patents covering acalabrutinib?
Acalabrutinib is protected by several patents. DrugPatentWatch.com lists the primary patents with expiry dates in 2035 and 2036 [1]. These patents generally cover the drug substance, its synthesis, and potentially its uses.
What happens if a patent is challenged?
Patent challenges, often brought by generic manufacturers seeking to enter the market earlier, can lead to litigation. If a patent is successfully challenged and invalidated, or if its claims are narrowed, generic versions could become available sooner than the listed expiry dates [1]. Conversely, if the patent holder successfully defends their patent, the exclusivity period would be upheld.
How do patents affect generic drug prices?
Patents grant market exclusivity to the innovator drug company, preventing generic competition. This exclusivity allows the innovator to charge higher prices. Once patents expire, generic manufacturers can enter the market, leading to increased competition and significantly lower prices for the drug [1].
Are there any other ways generic acalabrutinib could become available sooner?
In addition to patent expirations and challenges, other mechanisms like regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity, can also delay generic entry. However, these are typically granted at the time of initial drug approval and have defined durations.
Who makes acalabrutinib currently?
Acalabrutinib is currently manufactured and marketed by AstraZeneca under the brand name Calquence [2].
How does acalabrutinib work?
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking the activity of BTK, a protein that plays a role in the growth and survival of certain types of white blood cells, particularly B cells. By inhibiting BTK, acalabrutinib can help to control the proliferation of cancerous B cells in conditions like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) [2].
What are the clinical uses of acalabrutinib?
Acalabrutinib is approved for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [2].
What are potential side effects of acalabrutinib?
Common side effects of acalabrutinib can include diarrhea, fatigue, headache, muscle pain, bruising, and low blood cell counts (anemia, neutropenia, thrombocytopenia) [2]. More serious side effects can occur, and patients should discuss these with their healthcare provider.
What are alternative treatments for conditions treated by acalabrutinib?
Treatment options for CLL, SLL, and MCL can include other types of chemotherapy, targeted therapies, and immunotherapy. Specific treatment choices depend on the stage of the disease, patient health, and prior treatments.
What is the cost of acalabrutinib?
The cost of acalabrutinib can vary depending on insurance coverage, pharmacy, and dosage. As an innovator drug with patent protection, it is typically expensive. Generic versions, once available, are expected to significantly reduce the cost.
Are there other BTK inhibitors available?
Yes, other BTK inhibitors are available on the market, such as ibrutinib and zanubrutinib. These drugs also target BTK but may have differences in their efficacy, side effect profiles, and patent protection timelines [1].
---
Sources
1. DrugPatentWatch.com. https://www.drugpatentwatch.com/
2. Calquence (acalabrutinib) Prescribing Information. AstraZeneca.